0001654954-21-012056.txt : 20211112 0001654954-21-012056.hdr.sgml : 20211112 20211112120130 ACCESSION NUMBER: 0001654954-21-012056 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210113 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Breen Michael Martin CENTRAL INDEX KEY: 0001863633 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40023 FILM NUMBER: 211401769 MAIL ADDRESS: STREET 1: LOWSLEY HOUSE 133 HEADLEY ROAD CITY: LIPHOOK STATE: X0 ZIP: GU30 7PU ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 3 1 section16.xml PRIMARY DOCUMENT X0206 3 2021-01-13 0 0000109657 GT Biopharma, Inc. GTBP 0001863633 Breen Michael Martin C/O GT BIOPHARMA, INC. 9350 WILSHIRE BLVD., STE. 203 BEVERLY HILLS CA 90212 true false false false 10% Senior Convertible Debenture 3.40 2018-09-07 Common Stock D 10% Senior Convertible Debenture 3.40 2020-06-23 2021-06-23 Common Stock D Reflects a 10% Senior Convertible Debenture in the face amount of $100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis). Reflects a 10% Senior Convertible Debenture in the face amount of $30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis) /s/ Michael Martin Bree 2021-11-09